Mike Thompson, MD, PhD, FASCO
@mtmdphd.bsky.social
Views my own. VP Clinical Partnerships @TempusAI
#PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://coi.asco.org/share/RBB-TT6R/Michael
#PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://coi.asco.org/share/RBB-TT6R/Michael
Look up NCI and NCORP
September 30, 2025 at 2:43 PM
Look up NCI and NCORP
Increasing access = increasing cost to increase sites, staff, etc. That is not the mode the government is currently in. Look into NCCCP and NCORP NCI programs for more background
September 26, 2025 at 12:55 PM
Increasing access = increasing cost to increase sites, staff, etc. That is not the mode the government is currently in. Look into NCCCP and NCORP NCI programs for more background
Many publications on this. Short answer is 1) Improve access. 2) Remove I/E criteria that are not necessary. In the US ~85% of cancer patients are treated in the community setting. #ClinicalTrials
September 23, 2025 at 12:28 AM
Many publications on this. Short answer is 1) Improve access. 2) Remove I/E criteria that are not necessary. In the US ~85% of cancer patients are treated in the community setting. #ClinicalTrials
1) The demographics of MM are usually elderly. 2) Patients are treated by oncologists who monitor side effects -- on or off a study.
August 22, 2025 at 1:20 AM
1) The demographics of MM are usually elderly. 2) Patients are treated by oncologists who monitor side effects -- on or off a study.
Yes. Len and Dara-len are commonly used in MM therapy and tolerated
August 20, 2025 at 7:50 PM
Yes. Len and Dara-len are commonly used in MM therapy and tolerated